Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 47,100 shares, an increase of 20.8% from the May 31st total of 39,000 shares. Currently, 10.7% of the shares of the stock are sold short. Based on an average trading volume of 28,400 shares, the short-interest ratio is presently 1.7 days.

Windtree Therapeutics Price Performance

Windtree Therapeutics stock opened at $3.21 on Friday. Windtree Therapeutics has a 12-month low of $2.89 and a 12-month high of $30.06. The stock has a market capitalization of $1.89 million, a PE ratio of -0.09 and a beta of 0.62. The firm has a 50 day simple moving average of $3.96 and a 200-day simple moving average of $6.83.

Windtree Therapeutics (NASDAQ:WINT) last issued its quarterly earnings results on Tuesday, April 16th. The company reported ($13.31) earnings per share (EPS) for the quarter. On average, analysts forecast that Windtree Therapeutics will post -24.93 earnings per share for the current fiscal year.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.